Val66Met polymorphism and serum brain-derived neurotrophic factor in bipolar disorder: An open-label trial

Acta Psychiatrica Scandinavica

Volumn 129, Issue 5, 2014, Pages 393-400

  Grande, I ^a   Magalhaes P V S ^b   Chendo, I ^c   Stertz, L ^b,d   Fries, G R ^b,d   Cereser, K M ^b   Cunha, A B M ^e   Goi P ^b   Kunz, M ^b   Udina, M ^a   Martin Santos R ^a   Frey, B N ^f   Vieta, E ^a   Kapczinski, F ^b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c HOSPITAL DE SANTA MARIA   (Portugal)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

Biomarkers; Bipolar disorder; Brain derived neurotrophic factor; Quetiapine; Treatment response

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; QUETIAPINE; BIOLOGICAL MARKER; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; METHIONINE; PSYCHOTROPIC AGENT; VALINE;

ACUTE DISEASE; ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE DURATION; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN STUDY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; UNSPECIFIED SIDE EFFECT; AFFECT; AFFECTIVE SYMPTOMS; AMINO ACID SUBSTITUTION; BLOOD; BRAZIL; DRUG MONITORING; GENETIC POLYMORPHISM; GENETICS; LONGITUDINAL STUDY; NERVE CELL PLASTICITY; PATIENT ACUITY; PHYSIOLOGY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY;

ADULT; AFFECT; AFFECTIVE SYMPTOMS; AMINO ACID SUBSTITUTION; BIOLOGICAL MARKERS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; BRAZIL; DRUG MONITORING; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; METHIONINE; NEURONAL PLASTICITY; PATIENT ACUITY; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; VALINE;

EID: 84890128952     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12192     Document Type: Article

References (44)

1. Soeiro-De-souza MG, Dias VV, Figueira ML et al. Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder. Acta Psychiatr Scand 2012;126:332-341.
2. Grande I, Magalhaes PV, Kunz M, Vieta E, Kapczinski F. Mediators of allostasis and systemic toxicity in bipolar disorder. Physiol Behav 2012;106:46-50.
3. Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nat Rev Neurosci 2013;14:7-23.
4. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006;59: 1116-1127.
5. Post RM. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res 2007;41:979-990.
6. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011;35:804-817.
7. Dias VV, Balanza-Martinez V, Soeiro-De-souza MG et al. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr Scand 2012;126:315-331.
8. Grande I, Fries GR, Kunz M, Kapczinski F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig 2010;7:243-250.
9. Bus BA, Molendijk ML, Penninx BJ et al. Determinants of serum brain-derived neurotrophic factor. Psychoneuroendocrinology 2011;36:228-239.
10. Berry A, Bellisario V, Capoccia S et al. Social deprivation stress is a triggering factor for the emergence of anxiety- and depression-like behaviours and leads to reduced brain BDNF levels in C57BL/6J mice. Psychoneuroendocrinology. England: 2011 Elsevier Ltd. 2012;37:762-772.
11. Egan MF, Kojima M, Callicott JH et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell United states ; 2003;112:257-269.
12. Green EK, Raybould R, Macgregor S et al. Genetic variation of brain-derived neurotrophic factor (BDNF) in bipolar disorder: case-control study of over 3000 individuals from the UK. Br J Psychiatry England; 2006;188:21-25.
13. Muller DJ, De Luca V, Sicard T, King N, Strauss J, Kennedy JL. Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder: family-based association study. Br J Psychiatry England; 2006;189:317-323.
14. Strauss J, Barr CL, George CJ et al. Brain-derived neurotrophic factor variants are associated with childhood-onset mood disorder: confirmation in a Hungarian sample. Mol Psychiatry England; 2005;10:861-867.
15. Cunha ABM, Frey BN, Andreazza AC et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett 2006;398:211-215.
16. Kapczinski F, Dal-Pizzol F, Teixeira AL et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res 2011;45:156-161.
17. Fernandes BS, Gama CS, Cereser KM et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011;45:995-1004.
18. Kapczinski F, Vieta E, Andreazza AC et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008;32:675-692.
19. Palomino A, Vallejo-Illarramendi A, Gonzalez-Pinto A et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res the Netherlands; 2006;86:321-322.
20. Tramontina JF, Andreazza AC, Kauer-Sant'anna M et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett 2009;452:111-113.
21. Grande I, Kapczinski F, Stertz L et al. Peripheral brain-derived neurotrophic factor changes along treatment with extended release quetiapine during acute mood episodes: an open-label trial in drug-free patients with bipolar disorder. J Psychiatr Res 2012;46:1511-1514.
22. Vilela JAA, Crippa JAS, Del-Ben CM, Loureiro SR. Reliability and validity of a Portuguese version of the Young Mania Rating Scale. Braz J Med Biol Res 2005;38:1429-1439.
23. Fleck MPA, Poirierlittre MF, Guelfi JD, Bourdel MC, Loo H. Factorial structure of the 17-item hamilton depression rating-scale. Acta Psychiatr Scand 1995;92:168-172.
24. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997;73:159-171.
25. Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental-health outcome scale - reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995;166:654-659.
26. Tohen M, Frank E, Bowden CL et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009;11:453-473.
27. Tramontina J, Frey BN, Andreazza AC, Zandona M, Santin A, Kapczinski F. Val66met polymorphism and serum brain-derived neurotrophic factor levels in bipolar disorder. Mol Psychiatry 2007;12:230-231.
28. Willett JB, Singer JD, Martin NC. The design and analysis of longitudinal studies of development and psychopathology in context: statistical models and methodological recommendations. Dev Psychopathol 1998;10:395-426.
29. Matsuo K, Nicoletti MA, Peluso MA et al. Anterior cingulate volumes associated with trait impulsivity in individuals with bipolar disorder. Bipolar Disord Denmark; 2009;11:628-636.
30. Rybakowski JK, Borkowska A, Skibinska M, Hauser J. Illness-specific association of val66met BDNF polymorphism with performance on Wisconsin Card Sorting Test in bipolar mood disorder. Mol Psychiatry England; 2006;11:122-124.
31. Verhagen M, van der Meij A, van Deurzen PA et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. Mol Psychiatry 2010;15:260-271.
32. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008;64:527-532.
33. Rybakowski JK, Suwalska A. Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol 2010;13:617-622.
34. Kurita M, Nishino S, Kato M, Numata Y, Sato T. Plasma brain-derived neurotrophic factor levels predict the clinical outcome of depression treatment in a naturalistic study. PLoS ONE United States; 2012;7:e39212.
35. Molendijk ML, Bus BA, Spinhoven P et al. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry England; 2011;16: 1088-1095.
36. Kauer-Sant'anna M, Kapczinski F, Andreazza AC et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009;12:447-458.
37. Kapczinski F, Dal-Pizzol F, Teixeira AL et al. A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol Psychiatry 2010;15:784-786.
38. Magalhaes PVS, Jansen K, Pinheiro RT et al. Systemic toxicity in early-stage mood disorders. J Psychiatr Res 2011;45:1407-1409.
39. Vieta E. Mood stabilization in the treatment of bipolar disorder: focus on quetiapine. Hum Psychopharmacol 2005;20:225-236.
40. Martinowich K, Lu B. Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 2008;33:73-83.
41. Reinares M, Papachristou E, Harvey P et al. Towards a clinical staging for bipolar disorder: defining patient subtypes based on functional outcome. J Affect Disord 2013;144:65-71.
42. Vieta E, Popovic D, Rosa AR et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. Eur Psychiatry 2013;28:21-29.
43. Pan WH, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998;37:1553-1561.
44. Magalhaes PVS, Fries GR, Kapczinski F. Peripheral markers and the pathophysiology of bipolar disorder. Revista De Psiquiatria Clinica 2012;39:60-67.